Publicaciones (54) Publicaciones en las que ha participado algún/a investigador/a

2021

  1. A Cytometrist's Guide to Coordinating and Performing Effective COVID-19 Research

    Cytometry Part A

  2. A multifactorial aetiology for dilated cardiomyopathy

    European Heart Journal - Case Reports

  3. A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect on platelet function and bleeding diathesis

    American Journal of Hematology

  4. Areas of Specific Subspecialization (ACE) in Pulmonology

    Archivos de Bronconeumologia

  5. Areas of Specific Subspecialization (ACE) in pulmonology

    Archivos de Bronconeumologia

  6. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  7. Authors reply to the letter to editor with regard to the article titled “Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping”

    Cytometry Part B - Clinical Cytometry

  8. C3G self-regulatory mechanism revealed: implications for hematopoietic malignancies

    Molecular and Cellular Oncology

  9. CIBERESUCICOVID: A strategic project for a better understanding and clinical management of COVID-19 in critical patients

    Archivos de Bronconeumologia

  10. COVID-19: What type of cytokine storm are we dealing with?

    Journal of Medical Virology

  11. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

    British Journal of Haematology

  12. Catatonia with glycine receptor antibodies: Heads up?

    Schizophrenia Research

  13. Combined Procedure of Percutaneous Mitral Valve Repair and Left Atrial Appendage Occlusion: A Multicenter Study

    JACC: Cardiovascular Interventions

  14. Combining immunomodulators and antivirals for COVID-19 – Authors' reply

    The Lancet Microbe

  15. Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)

    Annals of Hematology

  16. Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)

    Drugs

  17. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)

    Leukemia

  18. Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir (Infectious Diseases and Therapy, (2021), 10, 4, (2203-2222), 10.1007/s40121-021-00455-1)

    Infectious Diseases and Therapy

  19. Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020) (Clinical and Translational Oncology, (2021), 23, 5, (913-921), 10.1007/s12094-020-02533-1)

    Clinical and Translational Oncology

  20. Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)

    Critical Care